Last updated: February 19, 2026
MYRBETRIQ (mirabegron) is an oral medication approved for the treatment of overactive bladder (OAB). Its current patent protection and upcoming market exclusivity expiration present a critical juncture for investment analysis. The drug's efficacy and market position, juxtaposed with the imminent threat of generic competition, define its investment profile.
What is the Current Patent Status for MYRBETRIQ?
MYRBETRIQ's composition of matter patent has expired. The primary patent, U.S. Patent No. 7,214,677, claiming the compound mirabegron, expired on January 17, 2022. This expiration allows for the potential filing of Abbreviated New Drug Applications (ANDAs) by generic manufacturers. However, secondary patents related to its formulation, method of use, and manufacturing processes may still offer some degree of market protection.
Key Patents and Their Expiry Dates:
- U.S. Patent No. 7,214,677 (Composition of Matter): Expired January 17, 2022. This is the most significant patent, covering the active pharmaceutical ingredient (API) itself. Its expiration opens the door for generic entry.
- U.S. Patent No. 9,012,476 (Extended-Release Formulation): Expires September 29, 2026. This patent covers the specific extended-release tablet formulation of mirabegron, which is crucial for its once-daily dosing regimen. Challenges to this patent could accelerate generic entry.
- U.S. Patent No. 9,095,593 (Method of Treating Bladder Outlet Obstruction): Expires September 29, 2026. This patent claims a method of using mirabegron to treat conditions like bladder outlet obstruction, which is related to OAB.
- U.S. Patent No. 8,735,380 (Polymorph and Process): Expires May 27, 2031. This patent relates to specific crystalline forms (polymorphs) of mirabegron and methods for their preparation. Polymorph patents can be strong, but also subject to complex litigation.
- U.S. Patent No. 8,815,904 (Process for Preparing Mirabegron): Expires April 21, 2029. This patent covers a specific manufacturing process for mirabegron.
[1, 2, 3]
What is the Market Exclusivity Situation for MYRBETRIQ?
Beyond patent protection, regulatory exclusivities also influence market access. MYRBETRIQ received its New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) on June 28, 2011.
- 5-Year Exclusivity: This typically applies to new chemical entities. While mirabegron was a new entity, the composition of matter patent expired before the full 5-year exclusivity period concluded.
- 3-Year Exclusivity: This applies to new uses, formulations, or significant clinical investigations. The extended-release formulation likely qualified for some form of this exclusivity, but its precise duration and impact are interwoven with patent expiry.
- Orphan Drug Exclusivity: Mirabegron is not designated as an orphan drug.
- Pediatric Exclusivity: Anya (a pediatric formulation) received six months of pediatric exclusivity extension, which expired on January 17, 2023. [4]
The lack of robust, long-term regulatory exclusivities beyond the expired patent protection means that the primary barrier to generic competition is the secondary patent portfolio.
What is the Competitive Landscape for Mirabegron?
The OAB market is competitive, with several treatment options available. Mirabegron is a beta-3 adrenergic agonist, a distinct mechanism of action compared to anticholinergic agents, which have historically dominated OAB treatment.
Key Competitors and Their Mechanisms of Action:
- Anticholinergics: These are the most common OAB medications. Examples include:
- Oxybutynin (Ditropan XL, Gelnique)
- Tolterodine (Detrol LA)
- Solifenacin (Vesicare)
- Darifenacin (Enablex)
- Fesoterodine (Toviaz)
- Trospium (Sanctura XR)
These drugs work by blocking acetylcholine, a neurotransmitter that causes bladder muscle contractions. Their primary side effects include dry mouth, constipation, and blurred vision.
- Mirabegron (MYRBETRIQ): As a beta-3 adrenergic agonist, mirabegron relaxes the detrusor muscle of the bladder, increasing bladder capacity. Its key advantage over anticholinergics is a generally lower incidence of anticholinergic side effects.
- OnabotulinumtoxinA (Botox): Used for refractory OAB, injected directly into the bladder muscle. It has a different administration route and a higher risk profile, typically reserved for patients who have not responded to oral medications.
- Mirabegron/Vesicare Combination (Vibegron): A fixed-dose combination of mirabegron and solifenacin (Vesicare) was approved as Jamtara. This combination aims to provide broad OAB symptom control. However, Jamtara’s approval was later withdrawn by Astellas due to manufacturing issues. [5]
The existence of multiple therapeutic classes and branded agents for OAB means that market share is fragmented. Mirabegron's differentiation lies in its mechanism and tolerability profile.
What is the Market Size and Growth Potential for OAB Treatments?
The global OAB market is substantial and projected to grow. Factors driving this growth include an aging population, increased awareness of OAB symptoms, and the availability of new treatment options.
- Market Size: Estimates vary, but the global OAB market was valued at approximately USD 3.4 billion in 2022 and is forecast to grow at a compound annual growth rate (CAGR) of around 4-6% through 2030. [6, 7]
- Drivers:
- Increasing prevalence of OAB with age.
- Growing diagnosis rates due to increased patient and physician awareness.
- Development of novel therapies with improved efficacy and safety profiles.
- Expansion of healthcare access in emerging economies.
- Challenges:
- Patient underdiagnosis and undertreatment.
- Concerns about side effects of existing therapies.
- Reimbursement challenges for newer or more expensive treatments.
The OAB market's steady growth indicates continued demand for effective treatments, providing a foundation for both branded and generic mirabegron products.
What are the Risks Associated with MYRBETRIQ's Patent Expirations?
The primary risk is the loss of market exclusivity to generic competitors. The expiration of the composition of matter patent is a significant event.
- Generic Competition: Once the key patents expire, generic manufacturers can file ANDAs. If these applications are approved, they can launch bioequivalent and therapeutically equivalent versions of mirabegron at substantially lower prices. This typically leads to a rapid decline in the market share and revenue of the branded product.
- Litigation Risk: Astellas, the originator of MYRBETRIQ, may engage in patent litigation to defend its secondary patents (formulation, process, polymorph). These legal battles are costly, time-consuming, and their outcomes are uncertain. Successful challenges to these secondary patents by generic companies would further accelerate generic entry.
- Price Erosion: Even if some secondary patents remain valid, the mere prospect of generic entry often leads to price negotiations and reductions by the branded manufacturer to maintain market share, impacting profitability.
- Formulation Challenges: Generic companies must demonstrate bioequivalence for their proposed formulations. Any issues with meeting bioequivalence standards or manufacturing the extended-release formulation could delay their entry.
- Market Dynamics: The reaction of healthcare providers and payers to generic mirabegron will influence its uptake. Lower prices are expected to drive increased prescription volume, potentially expanding the overall mirabegron market size, but at the expense of the branded product's revenue.
The U.S. Patent No. 9,012,476 (Extended-Release Formulation) and U.S. Patent No. 8,735,380 (Polymorph and Process) are critical for Astellas to maintain any meaningful market protection beyond the expired composition of matter patent. Any litigation surrounding these patents will be a key indicator of future market dynamics.
What are the Investment Considerations for MYRBETRIQ?
The investment thesis for MYRBETRIQ hinges on its remaining patent life, the strength of its secondary patent portfolio, the competitive landscape, and the overall OAB market dynamics.
Key Investment Factors:
- Remaining Patent Protection: While the composition of matter patent has expired, the extended-release formulation patent (U.S. Patent No. 9,012,476) expiring in September 2026 provides a limited window of continued exclusivity. Any successful defense of this patent or the polymorph patent (U.S. Patent No. 8,735,380) expiring in 2031 will be crucial for Astellas.
- Generic Threat: The immediate threat comes from generic companies seeking to launch mirabegron products. The current status of ANDA filings and any potential patent litigation will dictate the timing and impact of generic entry.
- Market Position: MYRBETRIQ has established a market presence as an alternative to anticholinergics, particularly for patients experiencing anticholinergic side effects. Its ability to maintain a premium pricing position against generics will be challenged.
- Pipeline and Strategy: Astellas' strategy for managing the MYRBETRIQ franchise post-patent expiry is important. This could include developing new indications, lifecycle management initiatives, or leveraging existing technology for new products. The failure of the mirabegron/solifenacin combination (Jamtara) due to manufacturing issues highlights the complexities of product development.
- Financial Performance: Analyze Astellas' recent financial reports for MYRBETRIQ sales trends, gross margins, and R&D investment related to the franchise. This will reveal the product's current revenue contribution and profitability.
- OAB Market Growth: The continued growth of the OAB market offers a baseline of demand. Generic mirabegron may even capture a larger share of this growing market due to its lower price point.
For investors, the focus should be on the probability of successful patent litigation and the duration of any remaining market exclusivity. The decline in revenue from the branded product is anticipated following generic entry, but the speed and magnitude of this decline are subject to patent defense outcomes.
What is the Outlook for MYRBETRIQ's Revenue and Profitability?
The revenue and profitability outlook for MYRBETRIQ is bifurcated: strong performance prior to significant generic penetration, followed by a substantial decline.
- Pre-Generic Period: Sales are likely to remain robust as long as significant patent protection or market exclusivity is in place. MYRBETRIQ generated approximately $1.4 billion in net sales in fiscal year 2022 for Astellas. [8] This period represents the current revenue stream.
- Post-Generic Entry: Upon the widespread availability of generic mirabegron, the branded product's sales will contract sharply, mirroring trends seen with other branded drugs post-patent expiry. The price of generics is typically 80-90% lower than the branded product. This leads to a significant reduction in revenue for the branded manufacturer, although profitability may persist due to lower marketing and sales expenses.
- Impact of Secondary Patents: The specific expiry dates of the formulation and polymorph patents are critical. If the formulation patent (September 2026) holds, it could delay the full impact of generic competition until then. If it is successfully challenged, generic entry could occur sooner.
- Market Share Shift: While branded sales will decline, the overall usage of mirabegron (including generics) may continue to grow with the OAB market expansion. Generic manufacturers will aim to capture market share through aggressive pricing.
The investment scenario is one of a mature product facing inevitable generic competition. The question is not if revenue will decline, but when and how steeply, depending on the remaining patent defenses.
Key Takeaways
- MYRBETRIQ's composition of matter patent expired in January 2022, opening the door for generic mirabegron.
- Remaining patent protection relies on secondary patents for its extended-release formulation (expires September 2026) and polymorph/process (expires May 2031).
- The OAB market is substantial and growing, driven by an aging population and increased awareness.
- The primary investment risk is generic competition, which will lead to significant revenue decline for the branded product.
- The outcome of potential patent litigation concerning secondary patents will critically determine the timing and extent of generic impact.
- Astellas' historical sales for MYRBETRIQ were approximately $1.4 billion in FY2022, indicating its significant market contribution prior to widespread generic entry.
Frequently Asked Questions
1. When is the latest patent protection expected to expire for MYRBETRIQ?
The latest patent, U.S. Patent No. 8,735,380, related to specific polymorphs and manufacturing processes, is set to expire in May 2031.
2. What is the main difference between MYRBETRIQ and traditional OAB treatments like anticholinergics?
MYRBETRIQ is a beta-3 adrenergic agonist that relaxes the bladder muscle, while anticholinergics block acetylcholine to reduce bladder contractions. This difference in mechanism often results in fewer anticholinergic side effects (e.g., dry mouth, constipation) with MYRBETRIQ.
3. Can generic versions of MYRBETRIQ be manufactured and sold now, given the composition of matter patent expiry?
Generic companies can file Abbreviated New Drug Applications (ANDAs) now. However, they must ensure their products do not infringe on valid secondary patents, particularly those covering the extended-release formulation and manufacturing processes, which could delay market entry.
4. What was the revenue generated by MYRBETRIQ in its most recent reported fiscal year?
MYRBETRIQ generated approximately $1.4 billion in net sales for Astellas in fiscal year 2022.
5. What does the term "bioequivalence" mean in the context of generic drug approval?
Bioequivalence means that a generic drug is absorbed into the bloodstream at the same rate and to the same extent as the branded drug, demonstrating that it will have the same therapeutic effect and safety profile.
Citations
[1] U.S. Patent No. 7,214,677. (2007). Mirabegron. United States Patent and Trademark Office.
[2] U.S. Patent No. 9,012,476. (2015). Extended-release pharmaceutical composition comprising mirabegron. United States Patent and Trademark Office.
[3] U.S. Patent No. 8,735,380. (2014). Crystalline forms of mirabegron and processes for their preparation. United States Patent and Trademark Office.
[4] FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
[5] Astellas Pharma Inc. (2023). Astellas Announces Withdrawal of Jamtara™ (mirabegron/solifenacin) NDA in the U.S. [Press Release].
[6] Grand View Research. (2023). Overactive Bladder Treatment Market Size, Share & Trends Analysis Report.
[7] Fortune Business Insights. (2023). Overactive Bladder Treatment Market.
[8] Astellas Pharma Inc. (2023). Astellas Pharma Inc. Consolidated Financial Results for the Fiscal Year Ended March 31, 2023.
